RecruitingNCT06635954
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
Sponsor
Oxford Biodynamics Inc.
Enrollment
2,000 participants
Start Date
May 14, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- 18 years of age or older
- Stage III or IV cancer
- Selected by their healthcare provider to receive the Episwitch CiRT® test according to the current evidence-based schedule (per protocol) as part of their standard of practice.
- ECOG performance status ≤ 2
- Clinically eligible for ICI therapy
- Able to read, understand and provide written informed consent.
- Willing and able to comply with the study requirements
Exclusion Criteria3
- Pregnant or breastfeeding
- History of bone marrow or organ transplant
- Contra indication for receiving Immune Check Point inhibitor.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06635954
Related Trials
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
NCT055881411 location
Patient-Centered Assessment of Symptoms and Outcomes
NCT039526241 location
Tumor Related Epilepsy
NCT026393251 location
Improving Engagement in HIV and Cancer Care in Zimbabwe
NCT069343691 location
Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors
NCT074543307 locations